Is this your brand? Sign in to claim ownership.

Sign in to claim this brand

Biogenex Laboratories, Inc.

US

Last updated May 23, 2026

What Biogenex Laboratories, Inc. makes

Biogenex Laboratories, Inc. manufactures in vitro diagnostic (IVD) antibodies targeting specific cellular and tissue markers, including cytokeratin, Ki67, progesterone receptor, synaptophysin, chromogranin A, CD45, and CD31. Their portfolio also includes antibodies for melanoma-associated antigens (e.g., MELAN-A, MUM1/IRF4) and viral markers (e.g., adenovirus). Additionally, the company produces automated microscope slide staining systems for immunohistochemistry applications.

The company’s products are classified under FDA’s In Vitro Diagnostic Device regulations, with devices falling into Class I and Class II categories. These antibodies and staining systems are listed in the FDA’s Unique Device Identifier (UDI) database. Biogenex Laboratories, Inc. is based in the United States.

Written from this company's registered devices by an AI model, and not verified by a human reviewer.

Frequently asked questions

What types of medical devices does Biogenex Laboratories, Inc. manufacture?

Biogenex Laboratories, Inc. specializes in in vitro diagnostic (IVD) devices, primarily antibodies designed for immunohistochemistry. These antibodies target specific cellular and tissue markers such as cytokeratin, Ki67, progesterone receptors, synaptophysin, chromogranin A, CD45, CD31, and melanoma-associated antigens like MELAN-A and MUM1/IRF4. The company also produces automated microscope slide staining systems, which assist in the visualization of these markers for diagnostic purposes.

Where is Biogenex Laboratories, Inc. based?

Biogenex Laboratories, Inc. is headquartered in the United States. The company’s location is relevant for regulatory compliance and distribution, as its devices are designed and manufactured under U.S. regulatory oversight.

Which regulatory registries list Biogenex Laboratories, Inc.’s devices?

Biogenex Laboratories, Inc.’s devices are included in the FDA’s Unique Device Identifier (UDI) database. This registry helps track and identify medical devices authorized for use in the U.S., ensuring transparency and traceability for healthcare providers and regulators.

How are Biogenex Laboratories, Inc.’s devices classified under FDA regulations?

Biogenex’s devices fall under the FDA’s In Vitro Diagnostic Device regulations and are classified as either Class I or Class II. Class I devices generally pose minimal risk and require less regulatory scrutiny, while Class II devices involve moderate risk and may require specific controls to ensure safety and effectiveness. Classification depends on factors like the device’s intended use and potential health impact.

AI-generated from registry data and not verified by a human reviewer.

Information

Country
US
Address
—
Website
—
LinkedIn
—
Facebook
—
Email
—
Phone
—
PRRC Contact
—
EUDAMED SRN
—
FDA FEI Number
—
DUNS Number
—

Catalogue (756)

Page 12 of 16
DeviceModel / ReferenceRegistriesClassStatus
Anti-Cd79a MU414-5UC
FDA UDI
Class IActive
Anti-Herpes Simplex Virus Type I PU084-5UP
FDA UDI
Class IActive
Anti-Cd3 (t-Cell) AM322-5M
FDA UDI
Class IActive
H.pylori AY880-YCD
FDA UDI
Class IActive
Anti-P53 Protein MU195-5UC
FDA UDI
Class IActive
Anti-Ki67 MU410-5UC
FDA UDI
Class IActive
Anti-Vimentin MU074-5UC
FDA UDI
Class IActive
Anti-Ttf1 NU887-UC
FDA UDI
Class IActive
Anti-Atrx MUB05-5UC
FDA UDI
Class IActive
Anti-Afp MU008A-UC
FDA UDI
Class IActive
Anti-Oct-2 NU830-5UC
FDA UDI
Class IActive
Anti-Cd34 NU779-UC
FDA UDI
Class IActive
Anti-Melanoma MU001A-5UC
FDA UDI
Class IActive
Anti-Ttf1 AY887-YCD
FDA UDI
Class IActive
Anti-Cd 7 MU702-UC
FDA UDI
Class IActive
Anti-Actin MU128-5UC
FDA UDI
Class IActive
Anti-Kappa Light Chain MU980-5UC
FDA UDI
Class IActive
Anti-Cd38 AN769-5M
FDA UDI
Class IActive
Anti-Calretinin AM583-5M
FDA UDI
Class IActive
Anti-Cytokeratin 7 AX255-50D
FDA UDI
Class IActive
Anti-Smoothelin AMB40-5M
FDA UDI
Class IActive
Anti-Ep-Cam AN820-10M
FDA UDI
Class IActive
Anti-Cd3 (t-Cell) MU322-UC
FDA UDI
Class IActive
Anti-Thyroglobulin MU032-5UC
FDA UDI
Class IActive
Anti-SV40 T Ag AMB74-5M
FDA UDI
Class IActive
Anti-Pms2 AN844-5M
FDA UDI
Class IActive
Anti-Melanoma AM001-10M
FDA UDI
Class IActive
Anti-Cd43 AN748-5M
FDA UDI
Class IActive
Anti-Androgen Receptor AM256-10M
FDA UDI
Class IActive
Anti-Desmin AX072-YCD
FDA UDI
Class IActive
Anti-Cd5 NU824-UC
FDA UDI
Class IActive
Diluent HK156-5K
FDA UDI
Class IActive
Anti-Acth AM487-5M
FDA UDI
Class IActive
Anti-Egfr AN781-10M
FDA UDI
Class IActive
Anti-Wilm's Tumor AN940-5M
FDA UDI
Class IActive
Anti-Cytokeratin 18 AM143-5M
FDA UDI
Class IActive
Anti-Cea AM365-5M
FDA UDI
Class IActive
Anti-Cd15 AM302-5M
FDA UDI
Class IActive
Anti-Tdt NU881-UC
FDA UDI
Class IActive
Anti-PR (Insite) AX328-YCD
FDA UDI
Class IIActive
Anti-S100 AMA15-5M
FDA UDI
Class IActive
Hpv 14 Probe PR251-YAD
FDA UDI
Class IActive
Anti-Cea MU009-5UC
FDA UDI
Class IActive
Anti-Survivin AN826-5M
FDA UDI
Class IActive
Anti- Sarcomeric Actin AM511-5M
FDA UDI
Class IActive
Anti-Hsv I PU084-UP
FDA UDI
Class IActive
Anti-P63 AM418-10M
FDA UDI
Class IActive
Anti-Cd45 (lca) AX111-50D
FDA UDI
Class IActive
Anti-Cd79a NU719-5UC
FDA UDI
Class IActive
Anti-VIMENTIN AM163-10M
FDA UDI
Class IActive

Related Companies

Authorised Representatives

No authorised representatives on record.

Importers

Not available yet.

Notified Bodies

Not available yet.

Authorities

Not available yet.

FDA Recalls (11)

Recalls reported by this firm to the FDA. Listed at company level — FDA recall records don't identify a specific catalogue device.

Biogenex Laboratories, Inc. has 11 recall records initiated between February 9, 2006, and July 1, 2014, all of which are recorded as terminated. The reasons cited include potential product system failures that could cause operator exposure to Hemo-De solution, distribution without 510(k) approval, misbranding and mislabeling issues related to non-compliance with Analyte Specific Reagent (ASR) requirements, incorrect labeling of reagent contents and antibody cocktails, and a defective bulk reagent dispensing mechanism that could result in spills.

AI-generated summary of the recall records listed below. It describes what the records state and is not an assessment of this manufacturer.

DateRecall No.ClassStatusReason
Jul 1, 2014Z-2113-2014—terminated

Product was distributed without 510(k) approval.

Jan 23, 2009Z-1016-2010—terminated

Under certain conditions, product system failure has the potential to cause operator injury due to splash of Hemo-De solution.

Jan 24, 2008Z-1471-2008—terminated

Bulk reagent dispensing mechanism may break resulting in reagent spill and possible exposure to chemicals.

Oct 3, 2006Z-0217-2007—terminated

Mislabeling: The product's "contents section " labeling (outer box) is mislabeled incorrectly printed as '1 x 100 mL Alk Phos Label' which should read '1 x 100 mL HRP Label'. A second, smaller label, incorrectly reads "RTU MultiLink HPR/AEC" which should be labeled as "RTU MultiLink HPR". The reagent vials in the box are correctly labeled.

Sep 5, 2006Z-1519-06—terminated

Mislabeling: Anti-CD45 cocktail antibody mislabeled as Ki-67.

Jun 2, 2006Z-1439-06—terminated

Misbranding-The product labeling (label and insert) is misbranded in that the product does not comply with the labeling requirements for an Analyte Specific

Jun 2, 2006Z-1438-06—terminated

Misbranding-The product labeling (label and insert) is misbranded in that the product does not comply with the labeling requirements for an Analyte Specific Reagent (ASR).

Feb 9, 2006Z-0608-06—terminated

Products produce granular staining in immunostained tissue sections, which may lead to misdiagnosis due to false positive result.

Feb 9, 2006Z-0609-06—terminated

Products produce granular staining in immunostained tissue sections, which may lead to misdiagnosis due to false positive result.

Feb 9, 2006Z-0606-06—terminated

Products produce granular staining in immunostained tissue sections, which may lead to misdiagnosis due to false positive result.

Feb 9, 2006Z-0607-06—terminated

Products produce granular staining in immunostained tissue sections, which may lead to misdiagnosis due to false positive result.